Neurogen (NRGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (423)	9/26/2005 11:54:29 AM
From: tuck	Read Replies (1) of 523

Corgentech, through its merger with AlgoRx, has a VR1 program in PII: >>ALGRX 4975, a VR1 agonist, is being developed for site-specific, severe or intractable pain. These types of pain are poorly treated by existing drugs such as opioids, and use of ALGRX 4975 could result in the reduction in opioid side effects as well as shorter rehabilitation and shorter hospital stay. Phase 2 clinical trials are currently underway for post-surgical pain following a variety of surgeries including bunionectomies, total knee replacements and various abdominal surgeries. Additional Phase 2 trials are underway for Morton's neuroma and tendonitis. Its advantages over currently available therapies are that it is non-opioid based and it is long-acting, providing pain relief to many patients for weeks or months after a single treatment. ALGRX 4975 is a C-neuron anesthetic, based on capsaicin. The product is administered locally at the site of pain and selectively reduces pain in nerve endings.<< Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next